Display options
Cite
Schwartz JI, Larson PJ, Porras AG, et al. Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations. Clin Drug Investig. 2003;23(8):503-9doi: 10.2165/00044011-200323080-00002.
Schwartz, J. I., Larson, P. J., Porras, A. G., Viswanathan-Aiyer, K. J., Agrawal, N. G., Lasseter, K. C., Mazenko, R. S., Merschman, S. A., & Gertz, B. J. (2003). Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations. Clinical drug investigation, 23(8), 503-9. https://doi.org/10.2165/00044011-200323080-00002
Schwartz, Jules I, et al. "Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations." Clinical drug investigation vol. 23,8 (2003): 503-9. doi: https://doi.org/10.2165/00044011-200323080-00002
Schwartz JI, Larson PJ, Porras AG, Viswanathan-Aiyer KJ, Agrawal NG, Lasseter KC, Mazenko RS, Merschman SA, Gertz BJ. Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations. Clin Drug Investig. 2003;23(8):503-9. doi: 10.2165/00044011-200323080-00002. PMID: 17535062.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 2003;23(8):503-9. doi: 10.2165/00044011-200323080-00002.

Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.

Clinical drug investigation

Jules I Schwartz, Patrick J Larson, Arturo G Porras, Kala-Jyoti Viswanathan-Aiyer, Nancy G B Agrawal, Kenneth C Lasseter, Ralph S Mazenko, Sheila A Merschman, Barry J Gertz

Affiliations

  1. Merck Research Laboratories, Rahway, New Jersey and West Point, Pennslyvania, USA.

PMID: 17535062 DOI: 10.2165/00044011-200323080-00002

Abstract

OBJECTIVE: Rofecoxib suspension is a formulation developed to increase the convenience of rofecoxib therapy for patients who have difficulty swallowing tablets. This open-label, two-part study compared the single-dose pharmacokinetics of rofecoxib tablets and rofecoxib suspension in healthy subjects.

DESIGN AND STUDY PARTICIPANTS: Part I was a two-period crossover study that assessed the bioequivalence of the 12.5mg/5mL rofecoxib suspension and the 12.5mg rofecoxib tablet in 24 healthy subjects (12 men and 12 women). Part II was a crossover study in 24 additional healthy subjects (12 men and 12 women) that determined the bioequivalence of the rofecoxib 25mg/5mL suspension and the 25mg rofecoxib tablet.

RESULTS: No clinically meaningful differences between rofecoxib tablet and suspension were apparent with respect to the rofecoxib area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) and maximum plasma concentration (C(max)), the primary measures of bioequivalence. At the 12.5mg and 25mg doses, the 90% CI for the geometric mean ratio (suspension/tablet) of both AUC(0-infinity) and C(max) fell within the prespecified interval for bioequivalence (0.80-1.25).

CONCLUSIONS: The rofecoxib suspension is bioequivalent to the rofecoxib tablet at single oral doses of 12.5mg and 25mg in healthy volunteers. The convenience and ease of administration of rofecoxib suspension may translate into increased compliance with therapy compared with a conventional solid tablet formulation, particularly for elderly patients.

References

  1. J Chromatogr A. 2002 Mar 8;949(1-2):83-9 - PubMed
  2. J Rheumatol. 1999 Nov;26(11):2438-47 - PubMed
  3. Clin Ther. 1999 Oct;21(10):1653-63 - PubMed
  4. Arch Intern Med. 2000 Jun 26;160(12):1781-7 - PubMed
  5. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80 - PubMed
  6. Obstet Gynecol. 1999 Oct;94(4):504-8 - PubMed
  7. Arthritis Rheum. 2000 May;43(5):978-87 - PubMed
  8. Clin Pharmacol Ther. 1999 Mar;65(3):336-47 - PubMed
  9. JAMA. 1999 Nov 24;282(20):1929-33 - PubMed
  10. Br Med J (Clin Res Ed). 1982 Dec 11;285(6356):1717-9 - PubMed
  11. J Pharm Pharmacol. 1985 Feb;37(2):126-9 - PubMed
  12. Drugs. 1999 Sep;58(3):499-505; discussion 506-7 - PubMed
  13. Am J Hosp Pharm. 1983 Jun;40(6):946, 948 - PubMed
  14. J Clin Pharmacol. 1986 Feb;26(2):141-6 - PubMed
  15. Clin Ther. 1999 Jun;21(6):943-53 - PubMed
  16. Am J Orthop (Belle Mead NJ). 2001 Jan;30(1):40-8 - PubMed
  17. N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528 - PubMed

Publication Types